Borosil Scientific Limited reported a dramatic turnaround in profitability for the quarter ended June 30, 2026 (Q1FY27), with standalone net profit surging 1,390% year-on-year (YoY) to ₹6.84 crore. The Mumbai-based manufacturer of laboratory glassware and process systems also saw its consolidated net profit rise to ₹4.36 crore, reversing a consolidated loss of ₹42.10 lakh recorded in the corresponding period of FY26. This significant improvement underscores the company’s operational recovery, margin expansion, and the positive impact of excluding exceptional one-time charges that weighed on the previous year’s figures.

The Board of Directors approved the unaudited financial results on August 3, 2026. The results were reviewed by Chaturvedi & Shah LLP, the company’s statutory auditors, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Additionally, the company released an investor presentation on August 5, 2026, under Regulation 30 of the same regulations, highlighting its strategic positioning in the scientific instruments sector. The Board also approved amendments to its Employee Stock Option Plans (ESOPs), specifically the Special Purpose Employee Stock Option Plan 2023 and the BSL ESOS, subject to shareholder approval. These amendments allow for share allotment via a trust route and increase the maximum discount percentage for new option grants from 10% to 20%.

Financial Performance

Standalone revenue from operations rose 12.2% YoY to ₹99.90 crore, up from ₹89.01 crore in Q1FY26. Other income stood at ₹2.80 crore, contributing to a total income of ₹102.69 crore. Total expenses increased to ₹93.38 crore from ₹84.79 crore in the prior year period, driven primarily by higher employee benefits expense and other expenses. EBITDA grew 15.3% YoY to ₹11.50 crore, reflecting improved operating leverage.

On a consolidated basis, revenue from operations grew 11.2% YoY to ₹106.75 crore. The group reported a profit before tax of ₹5.98 crore, compared to a pre-tax loss of ₹4.08 crore in the previous year. Consolidated net profit attributable to owners of the company was ₹4.37 crore. Consolidated EBITDA expanded significantly by 50.1% YoY to ₹8.70 crore.

Segment Analysis

The scientific laboratory glass and equipment segment remained the primary growth driver. Standalone revenue from this segment increased 6.3% YoY to ₹59.83 crore, with segment profit rising to ₹12.54 crore. In contrast, the glassware segment, which includes pharmaceutical primary packaging, saw standalone revenue rise 19.4% to ₹38.36 crore, but the segment remained marginally profitable with a profit of ₹0.19 crore, compared to a loss of ₹2.40 crore in Q1FY26.

Consolidated segment revenue for the scientific division reached ₹66.68 crore, while the glassware segment contributed ₹38.36 crore. The 'Others' segment, comprising filter paper and related items, generated ₹1.71 crore in revenue.

What the Numbers Show

The dramatic improvement in net profit is largely attributable to the absence of exceptional items in the current quarter, whereas Q1FY26 included an exceptional expenditure of ₹6.61 crore towards a Voluntary Retirement Scheme (VRS) at the Nashik plant. Excluding these one-time costs, the operational profit before tax has improved significantly. Furthermore, gross margin pressure appears to have eased, as cost of materials consumed grew at a slower pace than revenue. The company also benefited from a reduction in finance costs, which fell to ₹0.10 crore from ₹0.18 crore YoY on a standalone basis.

The approved ESOP amendments signal management’s intent to retain talent through more flexible equity compensation structures. By allowing share acquisition via a trust route and increasing the discount limit, the company aims to enhance the attractiveness of its employee benefits program without immediate dilution from primary issuance. Shareholders will vote on these changes in the upcoming general meeting. The investor presentation highlights Borosil Scientific’s position as a leader in laboratory glassware, leveraging the 'Make in India' initiative and global shifts toward localized manufacturing to capture market share.

Borosil Scientific Ltd has announced a change in its senior management structure effective July 14, 2026, due to a reorganization of internal reporting protocols. Mr. Sharad Tiwari, who served as the Head of Sales for Domestic and International Pharmaceutical Primary Packaging, has ceased to be designated as a Senior Managerial Personnel. Despite this change in designation, the company confirmed that he continues to be associated with Borosil Scientific Ltd.

The disclosure was made to the stock exchanges in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing clarified that the cessation of Mr. Tiwari's status as Senior Managerial Personnel was strictly a result of the internal restructuring and did not involve a departure from the organization. He remains employed with the firm in a different capacity following the adjustment in the reporting hierarchy.

Role and Regulatory Compliance

Mr. Tiwari was responsible for overseeing sales operations across both domestic and international markets for the Pharmaceutical Primary Packaging division. The company emphasized that his continued association ensures stability in the division's operations despite the administrative reclassification. The notification was signed by Ramavtar Sharma, the Company Secretary & Compliance Officer, and submitted to BSE Limited and the National Stock Exchange of India Limited.

The filing detailed the specific regulatory provisions under which the information was disclosed, ensuring transparency regarding changes in key managerial personnel. The move aims to streamline the internal reporting structure within the organization.